Your search for ‘Fish & Richardson PC’ returned 46 results

The term "derivative" trade secrets is the basis of a new legal theory being shopped around to create broad trade secret liability where none exists.

Largely confined to cryptocurrency enthusiasts and startups until only recently, blockchain is now going mainstream and with it, there is a growing interest in IP protection.

The past several years arguably have been some of the best for the cannabis industry since marijuana was originally criminalized in the early 20th century.

Following on the heels of Matal v. Tam in 2017, the Supreme Court on Monday issued a 6-3 opinion in Iancu v. Brunetti striking down the Lanham Act's prohibition on "immoral" and "scandalous" trademarks, ...

This post is a part of a monthly series summarizing notable activity in patent litigation in the District of Massachusetts, including short summaries of substantive orders.

The Internet as we know it may soon be changing forever. From January 12, 2012, to April 12, 2012, the Internet Corporation for Assigned Names and Numbers (ICANN) is expected to accept applications for new generic top-level domain names (gTLDs) to the right of the dot, where .com is now.

The Plan focuses heavily on addressing the unlawful exploitation of IP theft as it manifests in the forms of counterfeiting and piracy.

On July 18, 2018, FDA released its "Biosimilars Action Plan" ("BAP") for balancing innovation and competition, accompanied by a press release from FDA Commissioner Scott Gottlieb.

Some commentators have suggested that since Hatch-Waxman actions share certain similarities with declaratory judgment ("DJ") actions to prevent future infringement

On May 25, 2018, regulations went into effect that limit the amount of WHOIS information that is publicly available online.

Bankruptcy presents risks for, among many others, IP licensees. Fortunately, there is a provision in the federal bankruptcy law that is designed to protect IP licensees when a licensor becomes insolvent.

Businesses invest significant time and resources toward creating and maintaining customer lists.

Two recent cases in the Eastern District of Texas touched on the federal patent preemption defense.

Decisions in the Amgen v. Sandoz case involving Sandoz's biosimilar versions of Amgen's Neupogen® and Neulasta® drugs have provided significant guidance to biosimilar litigants over the years.

This post is a part of a monthly series summarizing notable activity in patent litigation in the District of Massachusetts, including short summaries of substantive orders.

This post is a part of a monthly series summarizing notable activity in patent litigation in the District of Massachusetts, including short summaries of substantive orders.

The many discovery disputes between AbbVie and Boehringer Ingelheim over BI's biosimilar of HUMIRA® (adalimumab) in the Delaware District Court are providing insight on the bounds of discovery in BPCIA litigation.